Lcl161

Manufactured by Chemietek

LCL161 is a cell lysis reagent designed for the extraction and purification of cellular components, including proteins, nucleic acids, and organelles. The product is formulated to effectively disrupt cell membranes and release the contents of cells, enabling further downstream processing and analysis.

Automatically generated - may contain errors

Lab products found in correlation

αpd 1, by BioXCell (1 mentions) Cyclophosphamide, by Bio-Techne (1 mentions) Ab187091, by Abcam (1 mentions) Ab 33174, by Abcam (1 mentions) Ab105767, by Abcam (1 mentions) Mifn β, by PBL Assay Science (1 mentions) Cycloheximide (chx), by Merck Group (1 mentions) Z vad fmk, by Apexbio (1 mentions) Anti actin sc 1616, by Santa Cruz Biotechnology (1 mentions) Nbp1 77299, by Novus Biologicals (1 mentions) Mtnfα, by Thermo Fisher Scientific (1 mentions) Htnfα, by Thermo Fisher Scientific (1 mentions) Bapta am, by Bio-Techne (1 mentions) Mg132, by Merck Group (1 mentions) Anti flag, by Merck Group (1 mentions) Bafilomycin a1, by Merck Group (1 mentions) Lipopolysaccharides (lps), by Merck Group (1 mentions)

2 protocols using lcl161

Combination Therapy for Cancer Treatment

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

For drug dosage and route of administration, we followed reported methods [12 (link)]. In brief, cyclophosphamide (Cy) (Tocris Bioscience) was used at a final concentration of 100 mg/Kg and administrated intraperitoneally (i.p.) twice, each dose one week apart. When LCL161 (Chemietek) was used, 50 mg/Kg LCL161 was administrated via the oral gavage (o.g.) route. The checkpoint inhibitor α-PD-1 (BioXCell) was administrated intraperitoneally (i.p.) at a final concentration of 10 mg/Kg. One week after cancer implantation, both LCL161 and α-PD-1 were administrated on days 1, 4, 8, 11 as described in Figure 4A.

Villa N.Y., Rahman M.M., Mamola J., Sharik M.E., de Matos A.L., Kilbourne J., Lowe K., Daggett-Vondras J., D'Isabella J., Goras E., Chesi M., Bergsagel P.L, & McFadden G. (2022). Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma. Oncotarget, 13, 490-504.

+ Open protocol

+ Expand

Molecular Mechanisms of Cell Death

Check if the same lab product or an alternative is used in the 5 most similar protocols

The dimerizer (B/B) and its competitor (washout) were purchased from Clontech. The cytokines used were: mTNFα (Peprotech), mIFNβ (PBL Assay Science) and hTNFα (Peprotech). The SMAC mimetic and inhibitor of IAP (LCL-161) was purchased from Chemietek. Other reagents included CHX (C7698, sigma), Q-VD-OPh (qVD, A8165, Apexbio), 7-Cl-O-Nec-1 (Nec-1s, 504297, calbiochem), zVAD-fmk (A1902, Apexbio), MG132 (Sigma), Necrosulfonamide (NSA, calbiochem), LPS (Sigma), BAPTA-AM (Tocris) and Bafilomycin A1 (Sigma). Antibodies used for immunoblotting in this study were anti-actin (sc-1616, Santa Cruz) anti-FLAG (A8592, Sigma), anti-HA (H6908, Sigma), anti-hMLKL (M6697, Sigma), anti-mMLKL (AP14272b, Agent), anti-pMLKL (ab187091, Abcam), anti-RIPK3 (NBP1-77299, Novus), anti-ALIX (3A9, 2171S, Cell signaling Technology), anti-CHMP2B (ab33174, abcam), anti-CHMP4B (ab105767, abcam), anti-TSG101 (4A10, ab83, abcam) anti-TNF (Clone XT3.11 from BioXCell) and anti-IκBα (C-21, Santa Cruz).

Gong Y.N., Guy C., Olauson H., Becker J.U., Yang M., Fitzgerald P., Linkermann A, & Green D.R. (2017). ESCRT-III acts downstream of MLKL to regulate necroptotic cell death and its consequences. Cell, 169(2), 286-300.e16.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!